Subjective well-being, craving for Cannabis and compliance or medication switch in a randomised double blind study with Olanzapine and Risperidone

Academic Medical Centre (AMC) (The Netherlands)0 个研究点目标入组 120 人开始时间: 2005年5月16日最近更新: 2015年1月13日

适应症

试验速览

暂无简介。

•1. Patients should be able to understand the study description and give informed consent
•2. Diagnosis of schizophrenia, schizoaffective disorder or schizophreniform disorder according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)
•3. Patients experience a first or second psychotic episode
•4. Age is between 18 and 30 years
•5. No current use of clozapine
•6. Patients must be reliable. They must agree to co-operate with all tests and examinations required by the protocol

•1. Pregnancy
•2. Lactating women
•3. Female subject without adequate contraception
•4. Known hypersensitivity to any ingredient of olanzapine or risperidone
•5. Concomitant use of any other antipsychotic drug than olanzapine or risiperidone
•6. Patients are not allowed to have received depot anti-psychotics for a period of at least three months prior to the study
•7. Use of other psychotropic medication other than oxazepam or biperiden
•8. Narrow-angle glaucoma
•9. Known neurological or endocrine disease

发起方

Academic Medical Centre (AMC) (The Netherlands)